A Multicenter, Open-label, Noncomparative Study of Enzastaurin in Patients With Non-Hodgkin's Lymphomas.

Trial Profile

A Multicenter, Open-label, Noncomparative Study of Enzastaurin in Patients With Non-Hodgkin's Lymphomas.

Completed
Phase of Trial: Phase II

Latest Information Update: 13 Apr 2018

At a glance

  • Drugs Enzastaurin (Primary)
  • Indications B cell lymphoma; Chronic lymphocytic leukaemia; Cutaneous T cell lymphoma; Follicular lymphoma; Marginal-zone-B-cell-lymphoma; Non-Hodgkin's lymphoma; Peripheral T-cell lymphoma
  • Focus Therapeutic Use
  • Sponsors Eli Lilly
  • Most Recent Events

    • 09 Apr 2018 Status changed from active, no longer recruiting to completed.
    • 09 Feb 2018 Planned End Date changed from 1 Dec 2018 to 1 Feb 2018.
    • 01 Nov 2017 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top